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Although greater than 50% of Ewing tumours contain non-random cytogenetic aberrations in addition to the pathognomonic
22q12 rearrangements, little is known about their prognostic signiﬁcance. To address this question, tumour samples from 134
Ewing tumour patients were analysed using a combination of classical cytogenetics, comparative genomic and ﬂuorescence in
situ hybridisation. The evaluation of the compiled data revealed that gain of chromosome 8 occurred in 52% of Ewing tumours
but was not a predictive factor for outcome. Gain of 1q was associated with adverse overall survival and event-free survival in
all patients, irrespective of whether the tumour was localised or disseminated (overall survival: P=0.002 and P=0.029; event-
free survival: P=0.018 and P=0.010). Loss of 16q was a signiﬁcant predictive factor for adverse overall survival in all patients
(P=0.008) and was associated with disseminated disease at diagnosis (P=0.039). Gain of chromosome 12 was associated with
adverse event-free survival (P=0.009) in patients with localised disease. These results indicate that in addition to a 22q12
rearrangement conﬁrmation in Ewing tumours it is important to assess the copy number of 1q and 16q to identify patients
with a higher probability of adverse outcome.
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Skeletal and extraskeletal Ewing’s sarcoma (ES) and peripheral
primitive neuroectodermal tumours (pPNET) are characterised by
a high expression of the CD99 antigen (Ambros et al, 1991) and
the presence of the balanced translocation t(11;22)(q24;q12) or
related aberrations involving 22q12 (Aurias et al, 1983; Turc-Carel
et al, 1983; Becroft et al, 1984; Whang-Peng et al, 1984). Therefore,
small-blue-round-cell tumours of childhood and early adolescence
that show high CD99 expression and the presence of a 22q12 aber-
ration are often grouped under the term ‘Ewing tumours’ (ETs)
(Ambros et al, 1991) or ‘Ewing family of tumours’ (EFTs) (Delattre
et al, 1994).
The t(11;22)(q24;q12) that is present in 85–90% of ETs (Mitel-
man et al, 2001) generates a chimeric fusion transcript between the
EWS (22q12) and FLI1 (11q24) genes (Delattre et al, 1992; Zucman
et al, 1992). In the remaining cases, the EWS gene is rearranged
with other partners of the ETS oncogene family (for review see
Sandberg and Bridge, 2000). In addition to the rearrangements
involving 22q12, non-random chromosomal aberrations occur in
more than 50% of cytogenetically analysed ETs (Sandberg and
Bridge, 2000; Mitelman et al, 2001). Chromosome gain is the most
frequent event, of which trisomy 8 is the most common found in
almost 50% of the cases, with gains of 2, 12 and 20 also being
frequent non-random events (Mugneret et al, 1988; Kullendorff
et al, 1999). Additional structural aberrations are less common
than numerical changes, although unbalanced rearrangements
involving chromosomes 1 and 16 are quite frequently seen. In
the majority of these cases the net imbalance is gain of 1q with
simultaneous loss of 16q (Mugneret et al, 1988; Douglass et al,
1990; Hattinger et al, 1996; Armengol et al, 1997; Stark et al,
1997; Kullendorff et al, 1999; Tarkkanen et al, 1999).
To date only the presence of metastases at diagnosis has
constantly been reported to be a negative prognostic marker for
ET patients (Ju ¨rgens et al, 1988; Terrier et al, 1996; Cotterill et
al, 2000). In addition, in patients with localised disease, poor histo-
logical response to chemotherapy (Picci et al, 1997; Bacci et al,
2000), tumour volume (Ju ¨rgens et al, 1988; Koscielniak et al,
1992; Ahrens et al, 1999), primary tumour site and age less than
15 years at diagnosis have been variably associated with adverse
clinical outcome (Cotterill et al, 2000).
Clinical implications of genetic changes in ETs are poorly under-
stood. Type 1 EWS-FLI1 fusion transcripts were associated with
better outcome in patients with localised disease compared to all
other EWS fusion transcripts in few studies (Zoubek et al, 1994,
1996; de Alava et al, 1998). Recently, deletions of INK4A (9p21)
and TP53 alterations (17p13) appeared to deﬁne small groups of
patients with markedly poor outcome (Kovar et al, 1997; de Alava
et al, 2000; Wei et al, 2000). Besides molecular genetic markers of
possible prognostic value, increased copy number of chromosomes
8, 12, and of 1q and loss of 1p have been discussed to be associated
with an advanced stage of disease, but with conﬂicting evidence as
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(Douglass et al, 1990; Armengol et al, 1997; Maurici et al, 1998;
Hattinger et al, 1999; Kullendorff et al, 1999; Tarkkanen et al,
1999). As ETs are rare all these previous studies were performed
on small numbers of patients and could not reach ﬁrm conclusions
with regard to the prognostic impact of the additional genetic aber-
rations.
To ascertain the clinical signiﬁcance of the most frequent
additional cytogenetic events in a large series of patients with
ET, the present collaborative retrospective study was initiated.
Genetic data from clinically well documented ET patients were
collected and statistical analyses were performed in order to
elucidate correlations between genetic and clinical parameters
and to determine the inﬂuence of these parameters on the clin-
ical outcome.
PATIENTS AND METHODS
Patients and tumour specimens
Genetic and clinical data were collected from a series of 146
patients with ET from four different centres (Helsinki, Toronto,
Vienna, Zurich). Criteria for inclusion in the study were date of
diagnosis between January 1983 and October 1999 and conﬁrmed
diagnosis of ET either by positive CD99 staining and/or the
presence of a 22q12 rearrangement. Due to incomplete clinical
and/or genetic data 12 patients were excluded from statistical
analyses. Thus, 134 patients were included in the ﬁnal study repre-
senting consecutive series of ET patients for each of the four
centres: Helsinki (23 patients), Toronto (24 patients), Vienna (68
patients) and Zurich (19 patients).
The median age at diagnosis of ET was 13 years (range 4
months–37 years). Sixty-two patients were male (46%) and 72
female (54%). Chest wall (n=15), pelvis (n=14) and femur
(n=12) were the most frequent tumour sites at diagnosis in the
91 patients presenting with localised ET. The primary tumours
of the 43 patients with disseminated disease at diagnosis were
located most frequently in the pelvis (n=15). Other tumour loca-
tions were found in less than 10 patients each. In 121 patients,
tumour tissue at diagnosis was analysed, in four patients at both
diagnosis and relapse, and in nine patients at relapse. Published
chemotherapy regimens were applied to 120 patients: CESS-81
and CESS-86+91P (Ju ¨rgens et al, 1988) in two patients each,
CESS-86 (Ju ¨rgens et al, 1988) in 18 patients, CESS-91P (Ju ¨rgens,
1994) and Ewing-SF (Miser et al, 1987) in four patients each,
EICESS-92 (Zoubek et al, 1996) in 40 patients, CWS (Koscielniak
et al, 1992) in ﬁve patients, SSG IX (Elomaa et al, 2000) in 16
patients, SSG IX with reduced doses in one patient, Ewing-CA
(Zielenska et al, 2001) in 24 patients and Ewing-IL (Stark et al,
1997) in three patients. One patient received palliative therapy
(Wiklund et al, 1992) after ﬁrst relapse only. Thirteen patients
received chemotherapy regimens similar to published protocols
used in the other centres, and one patient did not receive
chemotherapy.
Genetic analysis
Tumour samples were analysed with complementary techniques.
Chromosome analysis was performed in all four centres accord-
ing to standard protocols (Dracopoli, 2001; ISCN, 1995).
Cytogenetic data were available in 93 cases, of which 68 have
been published in detail (Hattinger et al, 1996, 1999; Armengol
et al, 1997; Stark et al, 1997; Tarkkanen et al, 1999; Zielenska
et al, 2001).
Fluorescence in situ hybridisation (FISH) with centromere-speci-
ﬁc probes for chromosomes 1, 8, 12, 16 and X were performed
according to standard protocols (Dracopoli, 2001). To analyse
the copy number of 1p FISH with probes D1Z1 (1q12) and
D1Z2 (1p36) was performed on 58 cases as described previously
(Ambros et al, 1995; Hattinger et al, 1999, 2000). In 21 cases,
DNA copy number changes were also determined by comparative
genomic hybridisation (CGH) according to protocols described
in detail previously (Armengol et al, 1997; Tarkkanen et al,
1999). For tumour DNA extraction, only tumour tissues containing
more than 50% of tumour cells were accepted. In 11 cases without
cytogenetic information, 22q12 rearrangements were studied by
FISH using cosmid probes ﬂanking the EWS breakpoint region
at 22q12 according to a protocol previously described (Desmaze
et al, 1994). EWS fusion transcripts were detected by RT–PCR
in 59 cases as described (Delattre et al, 1994). In 45 patients,
tumours were analysed by one of the methods (cytogenetics: 16,
CGH: 5, FISH: 24), in 50 patients by two methods (cytogenetics
and CGH, FISH or RT–PCR: 38; RT–PCR and CGH or FISH:
12), in 37 by three methods (cytogenetics and FISH and CGH or
RT–PCR: 36; cytogenetics and CGH and RT–PCR: 1) and in
two patients by all four methods. For the ﬁnal evaluation of genetic
parameters analysed, data obtained by all techniques were consid-
ered. In cases of disagreement between the results obtained by
different techniques (two cases for del1p), this parameter was
scored as not evaluable.
Deﬁnition of genetic parameters for statistical evaluation
Numerical aberrations were evaluated as ‘gain’ or ‘loss’ of whole
chromosomes. For statistical analysis ‘gain’ was deﬁned as ‘plus
one or more copies in addition to the appropriate somy of the
analysed chromosome’. Isochromosomes were evaluated as ‘gain’.
In samples that were analysed only by FISH, the numbers of
centromere-speciﬁc hybridisation signals per nucleus were evalu-
ated for at least two different chromosomes and 100 to 200
nuclei per sample were counted. For touch preparations and cyto-
spin slides at least 5% of the counted nuclei had to contain the
abnormality. For parafﬁn embedded samples at least 7% of the
nuclei had to show three hybridisation signals to be evaluated as
trisomic (Zielenska et al, 2001). Structural aberrations were scored
as ‘present’ or ‘not present’.
Statistical analysis
Chi-square analysis was used to evaluate associations between
clinical and genetic parameters and to test the consistency of
data submitted from the different centres. Extent of disease at
diagnosis (localised versus disseminated), tumour site (axial vs
peripheral), age (515 years vs 515 years), sex, gain of chromo-
somes 8 and 12, gain of 1q, deletion of 1p and loss of 16q were
the parameters analysed. The probability of overall survival (OS)
and event-free survival (EFS) were estimated according to the
method of Kaplan–Meier (Kaplan and Meier, 1958). Duration
of EFS was computed from the date of diagnosis of ET to the
ﬁrst occurrence of disease, deﬁned as local or systemic relapse
or death. For the analyses of OS only death was considered as
an event. The clinical follow-up was collected up to 31st March
2000. Estimates of the 5-year-probability of OS and EFS were
given together with their 95% conﬁdence intervals according to
Dorey–Korn (Dorey and Korn, 1987). In addition, a propor-
tional hazard model according to Cox (1972) was ﬁtted. A
stepwise selection procedure was used to identify the most
important predictors among the genetic parameters, whereas all
clinical parameters were forced to be included in the model. A
P value 40.25, after adjustment for the effects of other variables,
was required for inclusion and retention in the model. The rela-
tive risk of failure (RHR) and the associated 95% conﬁdence
intervals were calculated with the coefﬁcient and standard error
from the Cox analyses. P values were from the likelihood ratio
test. Additionally, alternative models were compared on the basis
of Akaike’s (1972) information criterion. All analyses were
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patients with localised ET.
RESULTS
Genetic aberrations in Ewing tumours
Information on 22q12 rearrangements was available for 109 cases.
The classical t(11;22)(q24;12) and/or an EWS/FLI1 fusion tran-
script detected by classical cytogenetic analysis and/or RT–PCR,
respectively, were found in 86 ETs (79%). A further 11 (10%) were
positive for an EWS rearrangement by FISH using probes ﬂanking
the EWS breakpoint region on chromosome 22. Variant 22q12
rearrangements or deletions at 22q12 were found in 10 cases
(9%). Two cases were highly positive for CD99 only.
The most frequent numerical aberrations, irrespective of
subgroup, were gains of chromosomes 8 and 12, present in 68
(52%) and 36 (27%) of evaluable cases, respectively. Non-random
structural aberrations additional to 22q12 rearrangements, involved
the long arms of chromosomes 1 and 16 in 26 (21%) and 25 (21%)
cases, respectively. In 14 of these cases (56%), gain of 1q and loss of
16q were the result of the unbalanced translocation
t(1;16)(q10*21;q10*q13). Loss of whole chromosome 16 occurred
in seven cases (28%). Deletions of the short arm of chromosome 1,
with breakpoints ranging between 1p13-1p36.3, were found in 10 of
the cases analysed (8%). Other non-random aberrations found in
cases analysed by classical cytogenetic and/or CGH analysis were gain
of chromosomes 20 (12 cases, 13%), 5 (12 cases, 12%), 2 (11 cases,
11%), 7 (10 cases, 10%), and 14 (nine cases, 9%). Isochromosomes
of 8q were present in two cases, and in one case i(14)(q10) was found.
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Figure 1 Distribution and interrelation of chromosome 12 gain, 1q gain
and 16q loss in 46 out of 118 patients with Ewing tumours. None of these
aberrations was found in Ewing tumours of 72 patients.
Table 1 Overall survival rates according to clinical parameters and genetic aberrations of all patients with ET
and of patients with localised ET only
All patients with ET Patients with localised ET
Parameters No. of pts
a
5-year survival
% (95% CI) P
b No. of pts
c
5-year survival
% (95% CI) P
b
Disease at diagnosis
localised 91 72 (60–81)
disseminated 43 49 (32–65) 0.003
Tumor site
axial 78 51 (37–63) 50 61 (43–74)
extremities 56 82 (69–90) 0.005 41 86 (70–94) 0.029
Age
515 years 83 73 (60–82) 60 78 (64–87)
515 years 51 51 (34–66) 0.065 31 61 (40–77) 0.244
Sex
male 62 62 (46–74) 37 66 (47–81)
female 72 67 (54–77) 0.623 54 76 (60–86) 0.415
Chromosome 8
8 gain 68 60 (45–71) 43 74 (56–86)
no gain 63 71 (55–81) 0.249 46 69 (52–81) 0.326
Chromosome 12
12 gain 36 55 (37–72) 23 60 (38–78)
no gain 95 67 (55–77) 0.222 65 75 (61–85) 0.226
Chromosomes 8 and 12
8 gain 41 60 (42–73) 27 73 (51–86)
8+12 gain 26 57 (36–76) 18 61 (37–81)
12 gain 10 48 (23–76) 5 53 (20–87)
no gain 52 75 (58–85) 0.136 37 77 (57–88) 0.599
Chromosome 1
1q gain 26 46 (27–66) 14 53 (29–77)
no gain 98 72 (59–81) 0.002 69 78 (63–87) 0.029
Chromosome 1
1p deletion 10 50 (25–76) 6 50 (22–81)
no deletion 112 67 (55–76) 0.429 74 75 (61–84) 0.477
Chromosome 16
16q loss 25 43 (24–64) 12 54 (28–79)
no loss 94 71 (59–80) 0.008 66 76 (61–85) 0.297
aNumber of all patients except those of whom tumours were not evaluated for the particular parameter.
bP values were calcu-
lated by the log-rank test.
cNumber of patients with localised disease except those of whom tumours were not evaluated for
the particular parameter. CI=Conﬁdence interval.
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and 16q loss in 118 ETs evaluated for all three parameters are
shown in Figure 1. The associations between these three genetic
aberrations were statistically signiﬁcant (P50.0001). Interestingly,
gain of chromosome 8 was only associated with gain of chromo-
some 12 (P50.004). Seventy-two per cent of tumours with gain
of chromosome 8 had also gain of chromosome 12 whereas only
44% of tumours with normal copy numbers of chromosome 8
had gain of chromosome 12. These associations were independent
of whether the tumours were localised or disseminated. No associa-
tion was found between 1p deletions and the other genetic
parameters. The consistency of genetic data among the four coun-
tries was assessed by Chi-square analysis and no signiﬁcant
differences were detected (P40.1 for all analyses).
Correlations between genetic aberrations and clinical
parameters
Associations between clinical parameters and genetic aberrations
were found for 1q gain and 16q loss. Both aberrations correlated
with age at diagnosis 515 years (34% vs 13%, P=0.005 and 31%
vs 15%, P=0.035). In the subgroup of patients with localised
disease only 16q loss was still signiﬁcantly associated with age
515 years (P=0.047). The presence of 16q loss was also signiﬁ-
cantly associated with disseminated disease at diagnosis (32% vs
15%, P=0.038). Consistency among the four countries was seen
for sex and tumour site (P40.1), but not for age at diagnosis
(P50.0002). In Helsinki, more patients with an age older than
15 years at diagnosis were submitted compared to the other three
centres.
Analysis of overall and event-free survival
The median duration of follow-up for surviving patients was 5
years (range 8 months – 15 years). Five-year OS and EFS rates
for all ET patients included for statistical analysis and for the
subgroup of patients with localised ET at diagnosis are
summarised in Tables 1 and 2. Patients with localised disease
at diagnosis showed better OS than patients with disseminated
disease (P=0.003). Univariate analysis of OS and EFS estimates
revealed that tumour site was a predictive factor for OS as
patients with axial tumours had poorer outcomes (P=0.005 and
P=0.029).
Among the ﬁve genetic parameters tested, only gain of 1q was a
predictive factor for both adverse OS and EFS either in the total
group of patients (Figure 2A,B and Tables 1 and 2) as well as
in the subgroup of patients with localised disease (Table 2). Loss
of 16q was signiﬁcantly associated with adverse OS (P=0.008)
M
o
l
e
c
u
l
a
r
a
n
d
C
e
l
l
u
l
a
r
P
a
t
h
o
l
o
g
y
Table 2 Event-free survival rates according to clinical parameters and genetic aberrations of patients with ET
and of patients with localised ET only
All patients with ET Patients with localised ET
Parameters No. of pts
a
5-year EFS
% (95% CI) P
b No. of pts
c
5-year EFS
% (95% CI) P
b
Disease at diagnosis
localised 78 56 (41–68)
disseminated 31 35 (16–56) 0.069
Tumor site
axial 67 41 (24–55) 44 51 (31–68)
extremities 42 62 (44–76) 0.147 34 60 (41–76) 0.588
Age
515 years 63 56 (40–69) 49 60 (42–74)
515 years 46 42 (25–58) 0.116 29 50 (28–68) 0.302
Sex
male 50 46 (27–63) 32 51 (29–69)
female 59 53 (38–66) 0.758 46 59 (41–74) 0.923
Chromosome 8
8 gain 50 59 (40–73) 38 64 (42–78)
no gain 58 42 (27–57) 0.148 39 48 (30–65) 0.263
Chromosome 12
12 gain 29 46 (26–66) 20 37 (18–61)
no gain 78 52 (37–65) 0.393 56 64 (46–76) 0.009
Chromosomes 8 and 12
8 gain 33 42 (23–60) 22 58 (33–77)
8+12 gain 24 48 (25–70) 16 40 (18–67)
12 gain 5 40 (12–77) 4 25 (7–70)
no gain 45 60 (40–75) 0.287 34 68 (45–83) 0.037
Chromosome 1
1q gain 23 39 (21–60) 13 36 (16–63)
no gain 81 56 (40–68) 0.018 60 65 (47–78) 0.010
Chromosome 1
1p deletion 9 33 (12–65) 6 33 (12–70)
no deletion 92 53 (38–64) 0.246 64 60 (43–73) 0.153
Chromosome 16
16q loss 21 38 (19–62) 11 38 (16–68)
no loss 78 74 (38–66) 0.092 57 61 (43–74) 0.151
aNumber of all patients except those of whom tumours were not evaluated for the particular parameter.
bP values were calcu-
lated by the log-rank test.
cNumber of patients with localised disease except those of whom tumours were not evaluated for
the particular parameter. CI=Conﬁdence interval.
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signiﬁcant associations with outcome in the subgroup of patients
with localised disease. In contrast, gain of chromosome 8 was
not associated with clinical outcome in all evaluations. However,
in patients with localised disease, gain of chromosome 12 was
signiﬁcantly associated with poorer EFS (P=0.009) and combined
analysis of gain of chromosomes 8 and/or 12 identiﬁed four groups
of patients with localised disease and statistically signiﬁcant differ-
ent EFS rates (Figure 2D).
In the multivariate model, gain of 1q maintained its signiﬁcant
impact on survival (RHR=2, P=0.046) after adjustment for clinical
parameters. This was also true for loss of 16q (RHR=1.9, P=0.060).
In a stepwise selection procedure only gain of 1q met the 25% level
for entry into the model, which was expected because of the high
correlation seen between gain of 1q and loss of 16q.
DISCUSSION
In the present study, genetic and clinical data from 134 patients
with skeletal and extraskeletal ETs were collected from four centres
in order to determine whether chromosomal aberrations present in
addition to 22q12 rearrangements are of prognostic signiﬁcance.
Diagnosis of ET was conﬁrmed by high expression of the CD99
antigen and/or the presence of a 22q12 rearrangement. Tumour
samples were analysed using a combination of classical cytogenetic
analysis, FISH, CGH and/or RT–PCR.
In this series, evidence for 22q12 rearrangements was present in
98% of the cases analysed. Notably, as only 13% (11 out of 85) of
the cytogenetically analysed cases did not display chromosomal
aberrations in addition to a 22q12 rearrangement, this illustrates
the importance of genetic analysis by complementary techniques
to detect these additional genetic events. When compiling the data
of all samples analysed, gain of chromosome 8 was found in 52%
and of chromosome 12 in 28% of the cases. Gains of chromosomes
20, 5, 2, 7 and 14 were found in decreasing frequency in less than
14% of the cases and thus the results of the present study are
consistent with previous studies (Kullendorff et al, 1999). The most
frequent facultative structural aberrations were gains of 1q and loss
of 16q that were present in 21% each. The majority displayed one
or two der(16)t(1;16) chromosomes, thus having a genetic net
imbalance of 1q gain and 16q loss, which was a statistically signiﬁ-
cant association. In addition, chromosome 12 gain was associated
with gain of 1q and loss of 16q, but there was a relatively low
frequency of ETs that displayed 1q gain and/or 16q loss that did
not have gain of chromosome 12. These data suggest that tumours
with gain of chromosome 12 might have a tendency towards
acquiring structural alterations involving 1q and 16q and that these
structural chromosomal aberrations occur later than numerical
aberrations. Interestingly, although gain of chromosome 8 was
the most frequent numerical aberration, it was only signiﬁcantly
associated with gain of chromosome 12 in this study. Deletions
at 1p were not associated with one of the other frequent aberra-
tions, although this is possibly due to deletions at 1p being
present in only 8% of the cases analysed.
Previous studies have shown that the presence of metastases at
onset is the main adverse prognostic parameter for patients with
ET (Ju ¨rgens et al, 1988; Terrier et al, 1996; Cotterill et al, 2000).
In the present study, disseminated disease at diagnosis and axial
tumour site were signiﬁcantly associated with adverse OS, although
not with EFS. Among the genetic parameters evaluated for prog-
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Figure 2 Overall survival plots (A and C) and event-free survival plots (EFS) (B and D) for patients with Ewing tumours displaying (A) 1q gain (n=26) or
balanced ratios between 1p and 1q (n=98), (B) 1q gain (n=23) or balanced ratios between 1p and 1q (n=81), (C) 16q loss (n=25) or normal copy number
of chromosome 16 (n=94), and (D) gain of chromosome 8 (n=22), gain of chromosomes 8 and 12 (n=16), gain of chromosome 12 (n=4) or normal copy
numbers of chromosomes 8 and 12 (n=34).
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ã 2002 Cancer Research UK British Journal of Cancer (2002) 86(11), 1763–1769nostic clinical impact gain of 1q was a strong predictor for adverse
OS and EFS both in patients with localised disease and in the
entire study group. Gain of 1q has also been reported to be asso-
ciated with advanced disease stage in two other childhood
tumours, neuroblastoma (Hirai et al, 1999) and Wilms’ tumour
(Hing et al, 2001). 1q is known to contain several genes that might
contribute to the development and/or progression of human sarco-
ma (Forus et al, 1998; Knuutila et al, 1998). Loss of 16q correlated
signiﬁcantly with adverse OS in the entire study group but not in
the subgroup of patients with localised disease. This observation
could be due to the fact that 16q loss was signiﬁcantly associated
with disseminated disease at diagnosis. However, the biological
consequences of 1q gain and 16q loss remain to be elucidated.
Gains of chromosomes 8 and 12 for which trends toward worse
outcome have been reported (Armengol et al, 1997; Tarkkanen et
al, 1999) were not predictive factors for OS and EFS in the entire
study group. In contrast, within the group of patients with loca-
lised ET gain of chromosome 12 identiﬁed a subgroup of
patients with markedly poor clinical outcome.
Molecular studies have suggested that TP53 alterations (de Alava
et al, 2000), INK4A deletions (Wei et al, 2000), and type of the
EWS/FLI1 fusion transcript (Zoubek et al, 1994, 1996; de Alava
et al, 1998) are predictive prognostic factors in ETs. Unfortunately,
no study currently exists that provides molecular, cytogenetic,
histopathological and clinical data of a series of patients large
enough for statistical evaluation. The present study has shown that
data from a series of 134 ET patients compiled from four different
countries and obtained by complementary techniques enabled the
identiﬁcation of 1q gain as a negative prognostic marker for
patients with ET regardless of stage of disease. In addition, loss
of 16q is the ﬁrst genetic parameter that is associated signiﬁcantly
with disseminated disease at onset. Therefore, the copy number of
1q and 16q should be evaluated in addition to the presence of a
22q12 rearrangement in ETs to identify patients with a higher
probability of adverse outcome.
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